Erika Hamilton, Chair, Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post by Harold J. Burstein, Breast Cancer Specialist and Professor at Dana-Farber Cancer Institute and at Harvard Medical School, on X, adding:
“Interesting on the heels of adjuvant giredestrant positive data recently among all comers (ESR1 mt and wt) May be a function of combination w/ CDK. We have data that w/ CDK our ET backbone may matter less.”
Quoting Harold J. Burstein on X:
“persevERA oral SERD study (1st line ER+ MBC in combo with palbo) from Roche
reads out negative. Will it prompt reconsideration of oSERDs in ESR1 wt / less resistant populations including adjuvant trials and other CDK46i pairings?”
Other articles featuring Erika Hamilton and Harold J. Burstein on OncoDaily.